Vistagen Therapeutics (VTGN) Short-term Investments (2024 - 2026)

Vistagen Therapeutics has reported Short-term Investments for 3 years, with the latest figure at $14.6 million in Q1 2026.

• Quarterly Short-term Investments rose 9.46% year-over-year to $14.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 million (up 9.46% YoY) and the FY2026 annual result came in at $14.6 million, up 9.46% from the prior year.
• Short-term Investments rose to $14.6 million in Q1 2026 per VTGN's latest filing, from $14.4 million in the prior quarter.
• Over five years, Short-term Investments peaked at $14.6 million in Q1 2026 and troughed at $5.4 million in Q2 2024.
• A 3-year average of $12.9 million and a median of $14.0 million in 2024 frame the typical range for Short-term Investments.
• The widest YoY moves for Short-term Investments: up 160.65% in 2025, down 4.0% in 2025.
• Over 3 years, Short-term Investments stood at $13.8 million in 2024, then increased by 4.0% to $14.4 million in 2025, then gained by 1.49% to $14.6 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $14.6 million, $14.4 million, and $14.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.